Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning: A dose-ranging study

N. Levine, Robert T Dorr, G. A. Ertl, C. Brooks, David S Alberts

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

An open-label, dose-finding study of a superpotent melanotropic peptide [Nle4-D-Phe7]α-MSH1-13, called Melanotan-I (MT-I), was performed in eight male volunteers with 'tannable' skin types III-IV. This synthetic analog of α-melanocyte-stimulating hormone (α-MSH), was administered subcutaneously for 10 days at three dose levels of 0.16 mg/kg per dose, 0.26 mg/kg per dose and 0.4 mg/kg per dose. Skin pigmentation at eight anatomic sites was measured serially using light reflectance values quantitated as luminance (L-values) and blue-yellow hue (b-values). All subjects tanned during the course of the trial, but there was no evidence of improved tanning beyond that obtained at the 0.16 mg/kg dose (P = 0.04). The most responsive site of skin darkening was the forehead, followed by the cheek, chin, neck and forearm. The anterior leg and buttock did not darken. There were no toxicities of grade 2 or more by World Health Organization (WHO) criteria at the 0.16 mg/kg dose, whereas the two higher doses produced moderate gastrointestinal upset and some mild to moderate fatigue. The optimal dose for ten daily subcutaneous injections of this agent is 0.16 mg/kg per day.

Original languageEnglish (US)
Pages (from-to)127-132
Number of pages6
JournalJournal of Dermatological Treatment
Volume10
Issue number2
StatePublished - 1999

Fingerprint

Tanning
Melanocyte-Stimulating Hormones
Skin Pigmentation
Chin
Skin
Buttocks
Forehead
Cheek
Subcutaneous Injections
Forearm
Fatigue
Volunteers
Leg
Neck
Light
Peptides

Keywords

  • Synthetic melanotropin
  • Tanning

ASJC Scopus subject areas

  • Dermatology

Cite this

Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning : A dose-ranging study. / Levine, N.; Dorr, Robert T; Ertl, G. A.; Brooks, C.; Alberts, David S.

In: Journal of Dermatological Treatment, Vol. 10, No. 2, 1999, p. 127-132.

Research output: Contribution to journalArticle

@article{49b57fd2036b45599f6e984442d02ccc,
title = "Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning: A dose-ranging study",
abstract = "An open-label, dose-finding study of a superpotent melanotropic peptide [Nle4-D-Phe7]α-MSH1-13, called Melanotan-I (MT-I), was performed in eight male volunteers with 'tannable' skin types III-IV. This synthetic analog of α-melanocyte-stimulating hormone (α-MSH), was administered subcutaneously for 10 days at three dose levels of 0.16 mg/kg per dose, 0.26 mg/kg per dose and 0.4 mg/kg per dose. Skin pigmentation at eight anatomic sites was measured serially using light reflectance values quantitated as luminance (L-values) and blue-yellow hue (b-values). All subjects tanned during the course of the trial, but there was no evidence of improved tanning beyond that obtained at the 0.16 mg/kg dose (P = 0.04). The most responsive site of skin darkening was the forehead, followed by the cheek, chin, neck and forearm. The anterior leg and buttock did not darken. There were no toxicities of grade 2 or more by World Health Organization (WHO) criteria at the 0.16 mg/kg dose, whereas the two higher doses produced moderate gastrointestinal upset and some mild to moderate fatigue. The optimal dose for ten daily subcutaneous injections of this agent is 0.16 mg/kg per day.",
keywords = "Synthetic melanotropin, Tanning",
author = "N. Levine and Dorr, {Robert T} and Ertl, {G. A.} and C. Brooks and Alberts, {David S}",
year = "1999",
language = "English (US)",
volume = "10",
pages = "127--132",
journal = "Journal of Dermatological Treatment",
issn = "0954-6634",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning

T2 - A dose-ranging study

AU - Levine, N.

AU - Dorr, Robert T

AU - Ertl, G. A.

AU - Brooks, C.

AU - Alberts, David S

PY - 1999

Y1 - 1999

N2 - An open-label, dose-finding study of a superpotent melanotropic peptide [Nle4-D-Phe7]α-MSH1-13, called Melanotan-I (MT-I), was performed in eight male volunteers with 'tannable' skin types III-IV. This synthetic analog of α-melanocyte-stimulating hormone (α-MSH), was administered subcutaneously for 10 days at three dose levels of 0.16 mg/kg per dose, 0.26 mg/kg per dose and 0.4 mg/kg per dose. Skin pigmentation at eight anatomic sites was measured serially using light reflectance values quantitated as luminance (L-values) and blue-yellow hue (b-values). All subjects tanned during the course of the trial, but there was no evidence of improved tanning beyond that obtained at the 0.16 mg/kg dose (P = 0.04). The most responsive site of skin darkening was the forehead, followed by the cheek, chin, neck and forearm. The anterior leg and buttock did not darken. There were no toxicities of grade 2 or more by World Health Organization (WHO) criteria at the 0.16 mg/kg dose, whereas the two higher doses produced moderate gastrointestinal upset and some mild to moderate fatigue. The optimal dose for ten daily subcutaneous injections of this agent is 0.16 mg/kg per day.

AB - An open-label, dose-finding study of a superpotent melanotropic peptide [Nle4-D-Phe7]α-MSH1-13, called Melanotan-I (MT-I), was performed in eight male volunteers with 'tannable' skin types III-IV. This synthetic analog of α-melanocyte-stimulating hormone (α-MSH), was administered subcutaneously for 10 days at three dose levels of 0.16 mg/kg per dose, 0.26 mg/kg per dose and 0.4 mg/kg per dose. Skin pigmentation at eight anatomic sites was measured serially using light reflectance values quantitated as luminance (L-values) and blue-yellow hue (b-values). All subjects tanned during the course of the trial, but there was no evidence of improved tanning beyond that obtained at the 0.16 mg/kg dose (P = 0.04). The most responsive site of skin darkening was the forehead, followed by the cheek, chin, neck and forearm. The anterior leg and buttock did not darken. There were no toxicities of grade 2 or more by World Health Organization (WHO) criteria at the 0.16 mg/kg dose, whereas the two higher doses produced moderate gastrointestinal upset and some mild to moderate fatigue. The optimal dose for ten daily subcutaneous injections of this agent is 0.16 mg/kg per day.

KW - Synthetic melanotropin

KW - Tanning

UR - http://www.scopus.com/inward/record.url?scp=0032772131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032772131&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032772131

VL - 10

SP - 127

EP - 132

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

SN - 0954-6634

IS - 2

ER -